![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ELOB |
Gene summary for ELOB |
![]() |
Gene information | Species | Human | Gene symbol | ELOB | Gene ID | 6923 |
Gene name | elongin B | |
Gene Alias | SIII | |
Cytomap | 16p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q15370 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6923 | ELOB | GSM4909281 | Human | Breast | IDC | 3.09e-17 | 5.13e-01 | 0.21 |
6923 | ELOB | GSM4909282 | Human | Breast | IDC | 2.46e-41 | 6.97e-01 | -0.0288 |
6923 | ELOB | GSM4909285 | Human | Breast | IDC | 1.19e-15 | 4.57e-02 | 0.21 |
6923 | ELOB | GSM4909286 | Human | Breast | IDC | 1.38e-19 | 2.26e-01 | 0.1081 |
6923 | ELOB | GSM4909287 | Human | Breast | IDC | 1.04e-29 | 7.06e-01 | 0.2057 |
6923 | ELOB | GSM4909290 | Human | Breast | IDC | 1.80e-22 | 6.33e-01 | 0.2096 |
6923 | ELOB | GSM4909291 | Human | Breast | IDC | 1.96e-23 | 7.14e-01 | 0.1753 |
6923 | ELOB | GSM4909293 | Human | Breast | IDC | 7.72e-29 | 5.57e-01 | 0.1581 |
6923 | ELOB | GSM4909294 | Human | Breast | IDC | 2.71e-21 | 6.21e-01 | 0.2022 |
6923 | ELOB | GSM4909295 | Human | Breast | IDC | 4.53e-09 | 5.60e-01 | 0.0898 |
6923 | ELOB | GSM4909296 | Human | Breast | IDC | 2.05e-22 | 6.13e-01 | 0.1524 |
6923 | ELOB | GSM4909297 | Human | Breast | IDC | 1.84e-09 | 1.93e-01 | 0.1517 |
6923 | ELOB | GSM4909298 | Human | Breast | IDC | 8.34e-45 | 7.61e-01 | 0.1551 |
6923 | ELOB | GSM4909299 | Human | Breast | IDC | 2.03e-10 | 3.19e-01 | 0.035 |
6923 | ELOB | GSM4909300 | Human | Breast | IDC | 2.17e-04 | 2.82e-01 | 0.0334 |
6923 | ELOB | GSM4909301 | Human | Breast | IDC | 1.87e-97 | 1.03e+00 | 0.1577 |
6923 | ELOB | GSM4909302 | Human | Breast | IDC | 1.87e-08 | 4.24e-01 | 0.1545 |
6923 | ELOB | GSM4909303 | Human | Breast | IDC | 1.41e-04 | 4.99e-01 | 0.0438 |
6923 | ELOB | GSM4909304 | Human | Breast | IDC | 6.07e-75 | 9.14e-01 | 0.1636 |
6923 | ELOB | GSM4909305 | Human | Breast | IDC | 5.79e-20 | 4.18e-01 | 0.0436 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000635412 | Prostate | Tumor | DNA-templated transcription, elongation | 31/3246 | 91/18723 | 8.58e-05 | 8.53e-04 | 31 |
GO:000636812 | Prostate | Tumor | transcription elongation from RNA polymerase II promoter | 25/3246 | 69/18723 | 1.33e-04 | 1.23e-03 | 25 |
GO:004217628 | Skin | AK | regulation of protein catabolic process | 101/1910 | 391/18723 | 4.78e-19 | 9.43e-16 | 101 |
GO:190336228 | Skin | AK | regulation of cellular protein catabolic process | 72/1910 | 255/18723 | 3.99e-16 | 1.97e-13 | 72 |
GO:190305028 | Skin | AK | regulation of proteolysis involved in cellular protein catabolic process | 61/1910 | 221/18723 | 2.17e-13 | 6.12e-11 | 61 |
GO:200005828 | Skin | AK | regulation of ubiquitin-dependent protein catabolic process | 50/1910 | 164/18723 | 5.25e-13 | 1.41e-10 | 50 |
GO:003243428 | Skin | AK | regulation of proteasomal ubiquitin-dependent protein catabolic process | 41/1910 | 134/18723 | 5.64e-11 | 1.01e-08 | 41 |
GO:001049827 | Skin | AK | proteasomal protein catabolic process | 97/1910 | 490/18723 | 9.65e-11 | 1.54e-08 | 97 |
GO:006113628 | Skin | AK | regulation of proteasomal protein catabolic process | 50/1910 | 187/18723 | 1.09e-10 | 1.66e-08 | 50 |
GO:004573228 | Skin | AK | positive regulation of protein catabolic process | 57/1910 | 231/18723 | 1.72e-10 | 2.49e-08 | 57 |
GO:004316127 | Skin | AK | proteasome-mediated ubiquitin-dependent protein catabolic process | 84/1910 | 412/18723 | 3.96e-10 | 4.88e-08 | 84 |
GO:190336428 | Skin | AK | positive regulation of cellular protein catabolic process | 43/1910 | 155/18723 | 6.24e-10 | 6.48e-08 | 43 |
GO:000989627 | Skin | AK | positive regulation of catabolic process | 94/1910 | 492/18723 | 1.32e-09 | 1.26e-07 | 94 |
GO:004586228 | Skin | AK | positive regulation of proteolysis | 74/1910 | 372/18723 | 1.32e-08 | 8.20e-07 | 74 |
GO:003133127 | Skin | AK | positive regulation of cellular catabolic process | 80/1910 | 427/18723 | 5.42e-08 | 2.76e-06 | 80 |
GO:003243624 | Skin | AK | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 27/1910 | 90/18723 | 1.64e-07 | 6.97e-06 | 27 |
GO:200006026 | Skin | AK | positive regulation of ubiquitin-dependent protein catabolic process | 30/1910 | 107/18723 | 1.82e-07 | 7.44e-06 | 30 |
GO:190180024 | Skin | AK | positive regulation of proteasomal protein catabolic process | 30/1910 | 114/18723 | 8.13e-07 | 2.70e-05 | 30 |
GO:190305220 | Skin | AK | positive regulation of proteolysis involved in cellular protein catabolic process | 33/1910 | 133/18723 | 1.00e-06 | 3.21e-05 | 33 |
GO:00063549 | Skin | AK | DNA-templated transcription, elongation | 25/1910 | 91/18723 | 2.82e-06 | 7.60e-05 | 25 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0406616 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
hsa0406617 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
hsa0406623 | Breast | IDC | HIF-1 signaling pathway | 22/867 | 109/8465 | 1.36e-03 | 1.00e-02 | 7.50e-03 | 22 |
hsa0517014 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0406633 | Breast | IDC | HIF-1 signaling pathway | 22/867 | 109/8465 | 1.36e-03 | 1.00e-02 | 7.50e-03 | 22 |
hsa0517015 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0406642 | Breast | DCIS | HIF-1 signaling pathway | 22/846 | 109/8465 | 9.83e-04 | 7.05e-03 | 5.20e-03 | 22 |
hsa0517024 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0521123 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0406652 | Breast | DCIS | HIF-1 signaling pathway | 22/846 | 109/8465 | 9.83e-04 | 7.05e-03 | 5.20e-03 | 22 |
hsa0517034 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0521133 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa052119 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa0406618 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0517017 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa0521114 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa0406619 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ELOB | SNV | Missense_Mutation | novel | c.94G>C | p.Glu32Gln | p.E32Q | Q15370 | protein_coding | tolerated(0.2) | benign(0.078) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ELOB | SNV | Missense_Mutation | rs776112584 | c.202N>T | p.Arg68Trp | p.R68W | Q15370 | protein_coding | tolerated(0.06) | benign(0.043) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ELOB | SNV | Missense_Mutation | rs773606482 | c.377N>C | p.Met126Thr | p.M126T | Q15370 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ELOB | SNV | Missense_Mutation | rs762947231 | c.161G>A | p.Gly54Asp | p.G54D | Q15370 | protein_coding | tolerated(0.31) | benign(0.115) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ELOB | SNV | Missense_Mutation | c.218C>T | p.Ala73Val | p.A73V | Q15370 | protein_coding | deleterious(0.01) | benign(0.201) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ELOB | SNV | Missense_Mutation | c.380C>A | p.Ala127Asp | p.A127D | Q15370 | protein_coding | deleterious_low_confidence(0) | benign(0.055) | TCGA-AG-3890-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ELOB | SNV | Missense_Mutation | rs533452752 | c.323N>T | p.Ser108Leu | p.S108L | Q15370 | protein_coding | tolerated(0.07) | benign(0.437) | TCGA-2E-A9G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | CR |
ELOB | SNV | Missense_Mutation | novel | c.271G>A | p.Glu91Lys | p.E91K | Q15370 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ELOB | SNV | Missense_Mutation | c.329N>T | p.Ser110Ile | p.S110I | Q15370 | protein_coding | deleterious(0) | benign(0.386) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
ELOB | SNV | Missense_Mutation | novel | c.170T>C | p.Leu57Pro | p.L57P | Q15370 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |